

Elizabeth A Morgan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/421679/publications.pdf>

Version: 2024-02-01

78
papers

2,866
citations

236925
25
h-index

182427
51
g-index

78
all docs

78
docs citations

78
times ranked

6029
citing authors

#	ARTICLE	IF	CITATIONS
1	<sc>Epstein-Barr virus prevalence among subtypes of malignant lymphoma in Rwanda, 2012 to 2018. International Journal of Cancer, 2022, 150, 753-760.	5.1	4
2	Sex-Biased ZRSR2 Mutations in Myeloid Malignancies Impair Plasmacytoid Dendritic Cell Activation and Apoptosis. Cancer Discovery, 2022, 12, 522-541.	9.4	44
3	Core-binding factor acute myeloid leukemia with inv(16): Older age and high white blood cell count are risk factors for treatment failure. International Journal of Laboratory Hematology, 2021, 43, e19-e25.	1.3	6
4	Genomic landscape of cutaneous follicular lymphomas reveals 2 subgroups with clinically predictive molecular features. Blood Advances, 2021, 5, 649-661.	5.2	26
5	Cohesin mutations alter DNA damage repair and chromatin structure and create therapeutic vulnerabilities in MDS/AML. JCI Insight, 2021, 6, .	5.0	39
6	Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21). Blood Advances, 2021, 5, 2481-2489.	5.2	25
7	Myelodysplastic syndromes with no somatic mutations detected by next-generation sequencing display similar features to myelodysplastic syndromes with detectable mutations. American Journal of Hematology, 2021, 96, E420-E423.	4.1	5
8	Imaging of IgG4-Related Disease in the Head and Neck: A Systematic Review, Case Series, and Pathophysiology Update. Journal of Neuroradiology, 2021, 48, 369-378.	1.1	11
9	Detection of the KITD816V mutation in myelodysplastic and/or myeloproliferative neoplasms and acute myeloid leukemia with myelodysplasia-related changes predicts concurrent systemic mastocytosis. Modern Pathology, 2020, 33, 1135-1145.	5.5	12
10	Contribution of clonal hematopoiesis to adult-onset hemophagocytic lymphohistiocytosis. Blood, 2020, 136, 3051-3055.	1.4	15
11	Harmonization of the Essentials: Matching Diagnostics to Treatments for Global Oncology. JCO Global Oncology, 2020, 6, 1352-1356.	1.8	2
12	LIM domain only 2 (LMO2) expression distinguishes T-lymphoblastic leukemia/lymphoma from indolent T-lymphoblastic proliferations. Histopathology, 2020, 77, 984-988.	2.9	6
13	Comprehensive metagenomic analysis of blastic plasmacytoid dendritic cell neoplasm. Blood Advances, 2020, 4, 1006-1011.	5.2	10
14	Identification of germline variants in adults with hemophagocytic lymphohistiocytosis. Blood Advances, 2020, 4, 925-929.	5.2	8
15	Male-Biased Spliceosome Mutations in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Impair pDC Activation and Apoptosis. Blood, 2020, 136, 13-14.	1.4	1
16	Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression. Journal of Clinical Oncology, 2020, 38, 2380-2389.	1.6	110
17	Multicenter phase 2 study of daratumumab monotherapy in patients with previously treated Waldenström macroglobulinemia. Blood Advances, 2020, 4, 5089-5092.	5.2	5
18	NK-Cell Enteropathy and Similar Indolent Lymphoproliferative Disorders. American Journal of Clinical Pathology, 2019, 151, 75-85.	0.7	18

#	ARTICLE	IF	CITATIONS
19	Many faces of the same myeloid neoplasm: a case of leukaemia cutis with mixed histiocytic and Langerhans cell differentiation. <i>Journal of Clinical Pathology</i> , 2019, 72, 93-96.	2.0	4
20	Targeted inhibition of CD47-SIRPÎ± requires Fc-FcÎ³R interactions to maximize activity in T-cell lymphomas. <i>Blood</i> , 2019, 134, 1430-1440.	1.4	45
21	Variable loss of CD30 expression by immunohistochemistry in recurrent cutaneous CD30+ lymphoid neoplasms treated with brentuximab vedotin. <i>Journal of Cutaneous Pathology</i> , 2019, 46, 823-829.	1.3	10
22	Blastic Plasmacytoid Dendritic Cell Neoplasm: First Case Report From Rwanda and Review of the Literature. <i>Journal of Global Oncology</i> , 2019, 5, 1-6.	0.5	1
23	Genetic Testing in the Diagnosis and Biology of Myeloid Neoplasms (Excluding Acute Leukemias). <i>American Journal of Clinical Pathology</i> , 2019, 152, 302-321.	0.7	5
24	Proapoptotic protein BIM as a novel prognostic marker in mantle cell lymphoma. <i>Human Pathology</i> , 2019, 93, 54-64.	2.0	8
25	Mechanisms of Lymphoma Clearance Induced by High-Dose Alkylating Agents. <i>Cancer Discovery</i> , 2019, 9, 944-961.	9.4	36
26	Clinicopathologic and genetic characterization of nonacute NPM1-mutated myeloid neoplasms. <i>Blood Advances</i> , 2019, 3, 1540-1545.	5.2	44
27	Recurrent genetic HLA loss in AML relapsed after matched unrelated allogeneic hematopoietic cell transplantation. <i>Blood Advances</i> , 2019, 3, 2199-2204.	5.2	52
28	Clinical utility of targeted next-generation sequencingâ€‘based screening of peripheral blood in the evaluation of cytopenias. <i>Blood</i> , 2019, 134, 2222-2225.	1.4	21
29	Concomitant classic Hodgkin lymphoma and schistosomiasis. <i>American Journal of Hematology</i> , 2019, 94, 840-841.	4.1	1
30	Talazoparib Treatment Preferentially Depletes Cohesin-Mutant Clones in New In Vivo Models of Cohesin-Mutant Myeloid Diseases. <i>Blood</i> , 2019, 134, 560-560.	1.4	1
31	Intergenerational epigenetic inheritance of cancer susceptibility in mammals. <i>ELife</i> , 2019, 8, .	6.0	43
32	Lymphoma and Pathology in Sub-Saharan Africa. <i>Clinics in Laboratory Medicine</i> , 2018, 38, 91-100.	1.4	20
33	Clinicopathologic Features and Prognostic Impact of Lymph Node Involvement in Patients With Breast Implant-associated Anaplastic Large Cell Lymphoma. <i>American Journal of Surgical Pathology</i> , 2018, 42, 293-305.	3.7	80
34	Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models. <i>Nature Communications</i> , 2018, 9, 2024.	12.8	80
35	Genomic Analyses Identify Recurrent Alterations in Immune Evasion Genes in Diffuse Large B-Cell Lymphoma, Leg Type. <i>Journal of Investigative Dermatology</i> , 2018, 138, 2365-2376.	0.7	59
36	Coreâ€‘binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (lâ€‘CBF) Tj ETQq0 0 0 rgBT /Overlo	2.8	17

#	ARTICLE	IF	CITATIONS
37	Developmental Ontogeny of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Revealed By Recurrent High Burden Clonal Hematopoiesis, Including in "Skin-Only" Disease. <i>Blood</i> , 2018, 132, 2755-2755.	1.4	4
38	Recurrent Genetic HLA Loss in Acute Myeloid Leukemia Relapsed after Matched Unrelated Allogeneic Hematopoietic Cell Transplant. <i>Blood</i> , 2018, 132, 817-817.	1.4	0
39	Clinical Utility of Routine Targeted Next-Generation Sequencing of Peripheral Blood in the Evaluation of Patients with Cytopenias. <i>Blood</i> , 2018, 132, 3090-3090.	1.4	0
40	Targeted Inhibition of CD47-Sirp Alpha Requires Fc-Fc Gamma Receptor Interactions to Maximize Phagocytosis in T-Cell Lymphomas. <i>Blood</i> , 2018, 132, 339-339.	1.4	0
41	Clinical Characteristics of GNB1 and GNAS Mutations in an Unselected Cohort of 6,343 Patients with Hematologic Abnormalities. <i>Blood</i> , 2018, 132, 1819-1819.	1.4	1
42	Detection of activating <i>MAP2K1</i> mutations in atypical hairy cell leukemia and hairy cell leukemia variant. <i>Leukemia and Lymphoma</i> , 2017, 58, 233-236.	1.3	39
43	Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 1598-1605.	1.6	339
44	Morphological and immunophenotypical features of hairy cell leukaemia involving lymph nodes and extranodal tissues. <i>Histopathology</i> , 2017, 71, 112-124.	2.9	10
45	A novel in vivo model for studying conditional dual loss of <i>BLIMP1</i> and <i>p53</i> in B cells, leading to tumor transformation. <i>American Journal of Hematology</i> , 2017, 92, E138-E145.	4.1	3
46	IgM myeloma: A multicenter retrospective study of 134 patients. <i>American Journal of Hematology</i> , 2017, 92, 746-751.	4.1	45
47	Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on <i>BCL2</i> and Sensitive to Venetoclax. <i>Cancer Discovery</i> , 2017, 7, 156-164.	9.4	164
48	Multiplex CRISPR/Cas9-Based Genome Editing in Human Hematopoietic Stem Cells Models Clonal Hematopoiesis and Myeloid Neoplasia. <i>Cell Stem Cell</i> , 2017, 21, 547-555.e8.	11.1	71
49	Systematic <i>STAT3</i> sequencing in patients with unexplained cytopenias identifies unsuspected large granular lymphocytic leukemia. <i>Blood Advances</i> , 2017, 1, 1786-1789.	5.2	13
50	Flow cytometry minimal residual disease assessment in peripheral blood of adult acute lymphoblastic leukemia patients. <i>Journal of Clinical Oncology</i> , 2017, 35, e18517-e18517.	1.6	0
51	Targetable subsets of non-Hodgkin lymphoma in Malawi define therapeutic opportunities. <i>Blood Advances</i> , 2016, 1, 84-92.	5.2	6
52	Antagonizing Integrin $\alpha 2 \beta 1$ Increases Immunosuppression in Cancer. <i>Cancer Research</i> , 2016, 76, 3484-3495.	0.9	58
53	The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. <i>Cancer Cell</i> , 2016, 29, 574-586.	16.8	227
54	Pediatric-type nodal follicular lymphoma: a biologically distinct lymphoma with frequent <i>MAPK</i> pathway mutations. <i>Blood</i> , 2016, 128, 1093-1100.	1.4	126

#	ARTICLE	IF	CITATIONS
55	Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. <i>Blood</i> , 2016, 128, 195-203.	1.4	259
56	Case report and literature review: cardiac tamponade as a complication of pericardial extramedullary hematopoiesis. <i>Cardiovascular Pathology</i> , 2016, 25, 371-374.	1.6	5
57	Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation. <i>Cancer Discovery</i> , 2016, 6, 368-381.	9.4	215
58	T-Cell Lymphoma Patient-Derived Xenografts and Newly Developed Cell Lines Recapitulate Aspects of Disease Biology and Represent Novel Tools for Preclinical Drug Development. <i>Blood</i> , 2016, 128, 3015-3015.	1.4	1
59	Generation of Models of Human Hematologic Malignancies Using CRISPR Genome Engineering. <i>Blood</i> , 2016, 128, 741-741.	1.4	3
60	Clonal Hematopoiesis Associated with Adverse Outcomes Following Autologous Stem Cell Transplantation for Non-Hodgkin Lymphoma. <i>Blood</i> , 2016, 128, 986-986.	1.4	3
61	Systematic STAT3 Mutation Testing Identifies Patients with Unsuspected T-Cell Large Granular Lymphocytic Leukemia. <i>Blood</i> , 2016, 128, 919-919.	1.4	0
62	Dual Conditional Loss of BLIMP-1 and p53 in B-Cells Drives B-Cell Lymphomagenesis. <i>Blood</i> , 2016, 128, 4169-4169.	1.4	0
63	Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation. <i>British Journal of Haematology</i> , 2015, 169, 851-858.	2.5	63
64	Myeloid neoplasm demonstrating a <i>STAT5B-RARA</i> rearrangement and genetic alterations associated with all-trans retinoic acid resistance identified by a custom next-generation sequencing assay. <i>Journal of Physical Education and Sports Management</i> , 2015, 1, a000307.	1.2	13
65	CXCR4 Regulates Extra-Medullary Myeloma through Epithelial-Mesenchymal-Transition-like Transcriptional Activation. <i>Cell Reports</i> , 2015, 12, 622-635.	6.4	123
66	Proxe: A Public Repository of Xenografts to Facilitate Studies of Biology and Expedite Preclinical Drug Development in Leukemia and Lymphoma. <i>Blood</i> , 2015, 126, 3252-3252.	1.4	2
67	Idelalisib Given Front-Line for the Treatment of Chronic Lymphocytic Leukemia Results in Frequent and Severe Immune-Mediated Toxicities. <i>Blood</i> , 2015, 126, 497-497.	1.4	21
68	Physical Interaction Between Mutant Calreticulin and the Thrombopoietin Receptor Is Required for Hematopoietic Transformation. <i>Blood</i> , 2015, 126, LBA-4-LBA-4.	1.4	2
69	Phenotypic and Transcriptional Characterization of Non-Hodgkin Lymphomas from Malawi Defines Targetable Disease Subsets. <i>Blood</i> , 2015, 126, 2655-2655.	1.4	0
70	B and T-Cell Lymphoma Patient-Derived Xenografts Recapitulate Aspects of Disease Biology and Progression and Represent Novel Tools for Preclinical Drug Development. <i>Blood</i> , 2015, 126, 4001-4001.	1.4	0
71	Pediatric-Type Nodal Follicular Lymphoma in Children and Adults Is Nearly Genetically Silent and Biologically Distinct from Typical Follicular Lymphoma. <i>Blood</i> , 2015, 126, 3925-3925.	1.4	0
72	Incidence and Clinical Features of Extramedullary Multiple Myeloma in Patients Who Underwent Stem Cell Transplantation. <i>Blood</i> , 2014, 124, 5746-5746.	1.4	0

#	ARTICLE	IF	CITATIONS
73	PAX8 and PAX5 are differentially expressed in B-cell and T-cell lymphomas. Histopathology, 2013, 62, 406-413.	2.9	21
74	Immunohistochemical Detection of Hairy Cell Leukemia in Paraffin Sections Using a Highly Effective CD103 Rabbit Monoclonal Antibody. American Journal of Clinical Pathology, 2013, 139, 220-230.	0.7	30
75	Anaplastic Lymphoma Kinase-Positive Large B-Cell Lymphoma: An Underrecognized Aggressive Lymphoma. Advances in Hematology, 2012, 2012, 1-6.	1.0	25
76	Cutaneous Radiation-Associated Angiosarcoma of the Breast: Poor Prognosis in a Rare Secondary Malignancy. Annals of Surgical Oncology, 2012, 19, 3801-3808.	1.5	76
77	Diagnostic Accuracy of a Defined Immunophenotypic and Molecular Genetic Approach for Peripheral T/NK-Cell Lymphomas: A North American PTCL Study Group Project. Blood, 2012, 120, 1545-1545.	1.4	6
78	Infectious Granulomatous Dermatitis Associated With Rothia mucilaginosa Bacteremia: A Case Report. American Journal of Dermatopathology, 2010, 32, 175-179.	0.6	18